People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alumis Inc. | — | Biotechnology | Series D+ | $240.0M | $432.7M | 2021 |
| Interline Therapeutics, Inc. | — | Pharma | Series C | $92.6M | $1.1B | 2021 |
| Spear Bio Inc. | — | Biotechnology | Series C | $50.1M | $391.9M | 2024 |
Vikram Bajaj at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Vikram Bajaj on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Tananbaum | 2 | 6 |
| Srinivas Akkaraju | 1 | 10 |
| Richard Gaster | 1 | 7 |
| Alan Colowick | 1 | 7 |
| David Singer | 1 | 7 |
| John Wu | 1 | 4 |
| James B. Tananbaum | 1 | 4 |
| Peng Yin | 1 | 3 |
| Michael Natan | 1 | 3 |
| Mark Bradley | 1 | 3 |
| June Lee | 1 | 3 |
| Alan B. Colowick | 1 | 3 |
| Michael Rome | 1 | 3 |
| Sapna Srivastava | 1 | 3 |
| Zhengbin Yao | 1 | 2 |
| Michael Varney | 1 | 2 |
| John R. Schroer | 1 | 2 |
| MARTIN BABLER | 1 | 2 |
| Jay Parrish | 1 | 2 |
| Vikam Bajaj | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.